{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:53:50Z","timestamp":1790056430843,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0601-9","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T12:11:36Z","timestamp":1524485496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Yucai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"601_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"601_CR2","doi-asserted-by":"crossref","unstructured":"Diefenbach CS, et al. Hodgkin lymphoma: current status and clinical trial recommendations. J Natl Cancer Inst. 2017;109(4):djw249.","DOI":"10.1093\/jnci\/djw249"},{"key":"601_CR3","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377.","journal-title":"Blood"},{"key":"601_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.seminhematol.2016.05.011","volume":"53","author":"A Younes","year":"2016","unstructured":"Younes A, Ansell SM. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results. Semin Hematol. 2016;53:186\u20139.","journal-title":"Semin Hematol"},{"key":"601_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2141.1992.tb04591.x","volume":"82","author":"B Falini","year":"1992","unstructured":"Falini B, et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol. 1992;82:38\u201345.","journal-title":"Br J Haematol"},{"key":"601_CR6","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","volume":"25","author":"SM Ansell","year":"2007","unstructured":"Ansell SM, et al. Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764\u20139.","journal-title":"J Clin Oncol"},{"key":"601_CR7","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","volume":"111","author":"NL Bartlett","year":"2008","unstructured":"Bartlett NL, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848\u201354.","journal-title":"Blood"},{"key":"601_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","volume":"146","author":"A Forero-Torres","year":"2009","unstructured":"Forero-Torres A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171\u20139.","journal-title":"Br J Haematol"},{"key":"601_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/0140-6736(92)91135-U","volume":"339","author":"B Falini","year":"1992","unstructured":"Falini B, et al. Response of refractory Hodgkin\u2019s disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339:1195\u20136.","journal-title":"Lancet"},{"key":"601_CR10","first-page":"1779","volume":"8","author":"R Schnell","year":"2002","unstructured":"Schnell R, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2002;8:1779\u201386.","journal-title":"Clin Cancer Res"},{"key":"601_CR11","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812\u201321.","journal-title":"N Engl J Med"},{"key":"601_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","volume":"18","author":"MA Fanale","year":"2012","unstructured":"Fanale MA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:248\u201355.","journal-title":"Clin Cancer Res"},{"key":"601_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/cas.12435","volume":"105","author":"M Ogura","year":"2014","unstructured":"Ogura M, et al. Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105:840\u20136.","journal-title":"Cancer Sci"},{"key":"601_CR14","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"601_CR15","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","volume":"125","author":"AK Gopal","year":"2015","unstructured":"Gopal AK, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236\u201343.","journal-title":"Blood"},{"key":"601_CR16","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562\u20136.","journal-title":"Blood"},{"key":"601_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","volume":"120","author":"AK Gopal","year":"2012","unstructured":"Gopal AK, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120:560\u20138.","journal-title":"Blood"},{"key":"601_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","volume":"7","author":"NL Bartlett","year":"2014","unstructured":"Bartlett NL, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.","journal-title":"J Hematol Oncol"},{"key":"601_CR19","doi-asserted-by":"crossref","unstructured":"O'Connor OA, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19:257\u201366.","DOI":"10.1016\/S1470-2045(17)30912-9"},{"key":"601_CR20","unstructured":"Cerichione C, et al. High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma. Blood. 2017;130:2802."},{"key":"601_CR21","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"601_CR22","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Trans. 2015;21:2136\u201340.","journal-title":"Biol Blood Marrow Trans"},{"key":"601_CR23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood.V126.23.519.519","volume":"126","author":"R Chen","year":"2015","unstructured":"Chen R, et al. Post transplant outcome of a multicenter phase II study of brentuximab vedotin as first line salvage therapy in relapsed\/refractory HL prior to AHCT. Blood. 2015;126:519.","journal-title":"Blood"},{"key":"601_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284\u201392.","journal-title":"Lancet Oncol"},{"key":"601_CR25","unstructured":"Cassaday RD, et al. Radiographic and high-throughput sequencing (HTS)-based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (rel\/ref) classical Hodgkin lymphoma (cHL): updated results of a phase I\/II trial. Blood. 2017;130:2806."},{"key":"601_CR26","doi-asserted-by":"crossref","unstructured":"Garcia-Sanz R, et al. Brentuximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood. 2016;128:1109.","DOI":"10.1182\/blood.V128.22.1109.1109"},{"key":"601_CR27","doi-asserted-by":"crossref","unstructured":"LaCasce AS, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126:3982.","DOI":"10.1182\/blood.V126.23.3982.3982"},{"key":"601_CR28","doi-asserted-by":"crossref","unstructured":"Cole PD, et al. Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): a Children\u2019s Oncology Group (COG) report. J Clin Oncol. 2017;35:7527.","DOI":"10.1200\/JCO.2017.35.15_suppl.7527"},{"key":"601_CR29","doi-asserted-by":"crossref","unstructured":"Younes A, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348\u201356.","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"601_CR30","doi-asserted-by":"crossref","unstructured":"Connors JM, Ansell SM, Fanale M, Park SI, Younes A. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017;130:1375\u20137.","DOI":"10.1182\/blood-2017-05-784678"},{"key":"601_CR31","doi-asserted-by":"crossref","unstructured":"Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","DOI":"10.1056\/NEJMoa1708984"},{"key":"601_CR32","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374:2419\u201329.","journal-title":"N Engl J Med"},{"key":"601_CR33","doi-asserted-by":"crossref","unstructured":"Abramson JS, et al. Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: a phase II trial. J Clin Oncol. 2015;33:8505.","DOI":"10.1200\/jco.2015.33.15_suppl.8505"},{"key":"601_CR34","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","volume":"128","author":"A Kumar","year":"2016","unstructured":"Kumar A, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016;128:1458\u201364.","journal-title":"Blood"},{"key":"601_CR35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.V130.Suppl_1.734.734","volume":"130","author":"A Kumar","year":"2017","unstructured":"Kumar A, et al. A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2017;130:734.","journal-title":"Blood"},{"key":"601_CR36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood.V130.Suppl_1.736.736","volume":"130","author":"L-M Fornecker","year":"2017","unstructured":"Fornecker L-M, et al. PET-based response after 2 cycles of brentuximab vedotin in combination with AVD for first-line treatment of unfavorable early-stage Hodgkin lymphoma: first analysis of the primary endpoint of breach, a randomized phase II trial of Lysa-FIL-EORTC Intergroup. Blood. 2017;130:736.","journal-title":"Blood"},{"key":"601_CR37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V130.Suppl_1.733.733","volume":"130","author":"AM Evens","year":"2017","unstructured":"Evens AM, et al. Sequential brentuximab vedotin (Bv) before and after adriamycin, vinblastine, and dacarbazine (Bv-AVD) for older patients with untreated classical Hodgkin lymphoma (cHL): final results from a multicenter phase II study. Blood. 2017;130:733.","journal-title":"Blood"},{"key":"601_CR38","doi-asserted-by":"crossref","unstructured":"Park SI, et al. A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma. J Clin Oncol. 2016;34:7508.","DOI":"10.1200\/JCO.2016.34.15_suppl.7508"},{"key":"601_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/hon.2437_69","volume":"35","author":"SI Park","year":"2017","unstructured":"Park SI, et al. Brentuximab vedotin consolidation to reduce radiation use in patients with limited stage non-bulky Hodgkin lymphoma: an update from a phase 2 clinical trial. Hematol Oncol. 2017;35:81\u20132.","journal-title":"Hematol Oncol"},{"key":"601_CR40","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.3324\/haematol.2015.138388","volume":"101","author":"M Federico","year":"2016","unstructured":"Federico M, et al. Brentuximab vedotin followed by ABVD +\/\u2212 radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. Haematologica. 2016;101:e139\u201341.","journal-title":"Haematologica"},{"key":"601_CR41","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","volume":"18","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18:1680\u20137.","journal-title":"Lancet Oncol"},{"key":"601_CR42","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"Friedberg JW, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >\/=60 years with HL. Blood. 2017;130:2829\u201337.","journal-title":"Blood"},{"key":"601_CR43","doi-asserted-by":"crossref","unstructured":"Gallamini A, et al. A PHASE 1\/2 clinical trial of brentuximab-vedotin and bendamustin in elderly patients with previously untreated advanced Hodgkin lymphoma (HALO STUDY. NCT identifier : 02467946): preliminary report. Blood. 2016;128:4154.","DOI":"10.1182\/blood.V128.22.4154.4154"},{"key":"601_CR44","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126:2798\u2013804.","journal-title":"Blood"},{"key":"601_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/hon.2437_68","volume":"35","author":"A Gibb","year":"2017","unstructured":"Gibb A, et al. Results of a phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVITY). Hematol Oncol. 2017;35:80\u20131.","journal-title":"Hematol Oncol"},{"key":"601_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10428199809059232","volume":"31","author":"F Hartmann","year":"1998","unstructured":"Hartmann F, Renner C, Jung W, Pfreundschuh M. Anti-CD16\/CD30 bispecific antibodies as possible treatment for refractory Hodgkin\u2019s disease. Leuk Lymphoma. 1998;31:385\u201392.","journal-title":"Leuk Lymphoma"},{"key":"601_CR47","first-page":"1873","volume":"7","author":"F Hartmann","year":"2001","unstructured":"Hartmann F, et al. Anti-CD16\/CD30 bispecific antibody treatment for Hodgkin\u2019s disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res. 2001;7:1873\u201381.","journal-title":"Clin Cancer Res"},{"key":"601_CR48","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024\u201331.","journal-title":"Blood"},{"key":"601_CR49","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1182\/blood-2001-12-0295","volume":"100","author":"P Borchmann","year":"2002","unstructured":"Borchmann P, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002;100:3101\u20137.","journal-title":"Blood"},{"key":"601_CR50","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23:1156\u201366.","journal-title":"Clin Cancer Res"},{"key":"601_CR51","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127:3462\u201371.","journal-title":"J Clin Invest"},{"key":"601_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"key":"601_CR53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood.V126.23.583.583","volume":"126","author":"S Ansell","year":"2015","unstructured":"Ansell S, et al. Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). Blood. 2015;126:583.","journal-title":"Blood"},{"key":"601_CR54","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283\u201394.","journal-title":"Lancet Oncol"},{"key":"601_CR55","doi-asserted-by":"crossref","unstructured":"Timmerman JM, et al. Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed\/refractory classical Hodgkin lymphoma. Blood. 2016;128:1110.","DOI":"10.1182\/blood.V128.22.1110.1110"},{"key":"601_CR56","doi-asserted-by":"crossref","unstructured":"Armand P, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018; J Clin Oncol. 2018; JCO.2017.76.0793.","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"601_CR57","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/cas.13230","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci. 2017;108:1007\u201312.","journal-title":"Cancer Sci"},{"key":"601_CR58","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471\u20138.","journal-title":"Blood"},{"key":"601_CR59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V130.Suppl_1.651.651","volume":"130","author":"R Ramchandren","year":"2017","unstructured":"Ramchandren R, et al. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 study. Blood. 2017;130:651.","journal-title":"Blood"},{"key":"601_CR60","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","volume":"128","author":"S Ansell","year":"2016","unstructured":"Ansell S, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016;128:183.","journal-title":"Blood"},{"key":"601_CR61","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hon.2437_72","volume":"35","author":"CS Diefenbach","year":"2017","unstructured":"Diefenbach CS, et al. Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Hematol Oncol. 2017;35:84\u20135.","journal-title":"Hematol Oncol"},{"key":"601_CR62","doi-asserted-by":"crossref","unstructured":"Herrera AF, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2017;131:1183\u201394.","DOI":"10.1182\/blood-2017-10-811224"},{"key":"601_CR63","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733\u20139.","journal-title":"J Clin Oncol"},{"key":"601_CR64","doi-asserted-by":"crossref","unstructured":"Armand P, et al. Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b Keynote-013 Study. Blood. 2016;128:1108.","DOI":"10.1182\/blood.V128.22.1108.1108"},{"key":"601_CR65","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"601_CR66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/hon.2437_54","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, et al. Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (CHL). Hematol Oncol. 2017;35:67.","journal-title":"Hematol Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0601-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0601-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0601-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T18:19:53Z","timestamp":1661019593000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0601-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0601-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"57"}}